Trulieve's NYSE Bell Marks the End of a Corporate Journey — and the Start of a New Test

Trulieve completes Delaware redomiciliation and NYSE listing under TRLV, reporting Q2 revenue of $271M and reaffirming 2026 guidance despite insider sales.

The confetti has barely settled on the NYSE trading floor, but the real work for Trulieve is just beginning. When the company's executives rang the closing bell on August 18, they weren't just celebrating a listing — they were putting a public stamp on a months-long legal migration that fundamentally repositions the cannabis operator within the American capital markets.

The ceremonial moment capped a process that had been building for weeks. Shareholders gave their blessing at a special meeting on August 5, the Supreme Court of British Columbia issued its final order on August 10, and the paperwork went effective in Delaware the following day. With that, Trulieve formally shed its Canadian corporate identity and emerged as a Delaware-incorporated entity — a distinction that carries real weight in a sector where most operators have languished on OTC markets or secondary exchanges.

A Structural Shift With Symbolic Weight

The redomiciliation involved a one-for-one exchange of voting shares into Class A and Class B common stock of the new Delaware entity, executed under a Section 3(a)(10) exemption from US securities law. The subordinate voting shares continue trading on the NYSE under the familiar TRLV ticker, which has been live since June 10, 2026.

For a cannabis company, the Delaware move is more than administrative housekeeping. It signals a deliberate pivot toward US institutional investors, many of whom steer clear of foreign-incorporated equities. By pairing a Delaware domicile with a primary NYSE listing, Trulieve has carved out a first-mover position in a sector that has historically struggled to attract mainstream capital.

The Numbers Behind the Narrative

The fanfare coincides with a reporting period that gives investors something concrete to assess. On August 7, Trulieve posted second-quarter results for the period ending June 30: revenue of $271 million, adjusted EBITDA of $98 million, and free cash flow of $32 million. The quarter also saw the deconsolidation of Harvest operations in states with mixed medical and recreational markets — a structural cleanup that had been telegraphed in prior quarters.

Management used the August 9 earnings call to reaffirm full-year guidance. Operating cash flow is still expected to hit at least $225 million, while capital expenditures are projected to land between $60 million and $80 million. That range suggests a disciplined spending posture even as the company navigates its corporate transformation.

Cantor Fitzgerald weighed in on the same day as the earnings release, maintaining an Overweight rating with a $15.00 price target — a signal that at least one sell-side desk sees the operational story as intact.

Insider Activity Adds a Caveat

Not everything in the tape is celebratory. Filings over the past 90 days show insider sales of roughly 1.7 million shares, worth approximately $14.7 million. Such transactions are hardly unusual in the cannabis space, but they do invite scrutiny at a moment when the company is executing significant structural changes.

Management has also been working the investor circuit. CEO Kim Rivers was scheduled to appear in a fireside chat at the 46th Canaccord Genuity Growth Conference on August 12 — the kind of engagement that typically follows major corporate events, giving institutions a chance to press executives on strategy and address lingering questions.

What the Bell Doesn't Change

The NYSE listing and Delaware domicile don't alter the underlying business economics. What they potentially change is visibility — and access. US fund managers who routinely exclude foreign-domiciled names now have a cleaner path to Trulieve's equity. Whether that translates into a broader shareholder base is a question that will only be answered in the coming quarters, as the symbolism fades and the focus shifts back to execution.

For now, the company has laid down two structural pillars — a Delaware home and a Big Board listing — that distinguish it from the rest of the cannabis pack. The market's verdict on whether those pillars support a higher valuation will come with time, as operational results take over from ceremonial milestones.